Diligence memo · auto-generated · as of July 2, 2026
NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd. looks under-valued against its niche peers and is active on financing cadence.
Businessfiled
NLS Pharmaceutics Ltd. operates in Pharmaceuticals, based in ZURICH.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
NLS Pharmaceutics Ltd. has raised $27M in disclosed capital across 8 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $10M on 2022-12-13.
Most recent recorded round closed around 2025-06-27.
Valuation (modeled)modeled
Provath models NLS Pharmaceutics Ltd. at approximately $3.3M (range $1.1M–$5.7M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.20× the median modeled value of Series A Pharmaceuticals companies in 2025–2027 (37 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 5 months.
Last raise 12 mo ago; this sector typically re-raises about every 13 months.
Raising on or ahead of the sector's normal rhythm.
The last round was 2.0× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 71% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 6% of those peers.
Closest niche peers: Incannex Healthcare Inc., Retension Pharmaceuticals, Inc., Eikonoklastes Therapeutics, Inc., Phoenicis Therapeutics, Inc., Pharmaceutical Resource Technology, Inc..
Peoplefiled
22 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.